Evaluation of distal symmetric polyneuropathy: The role of laboratory and genetic testing (an evidence‐based review)
- 11 December 2008
- journal article
- review article
- Published by Wiley in Muscle & Nerve
- Vol. 39 (1) , 116-125
- https://doi.org/10.1002/mus.21226
Abstract
Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence‐based guidelines regarding the role of laboratory and genetic tests for the assessment of DSP. A literature review using MEDLINE, EMBASE, Science Citation Index, and Current Contents was performed to identify the best evidence regarding the evaluation of polyneuropathy published between 1980 and March 2007. Articles were classified according to a four‐tiered level of evidence scheme and recommendations were based on the level of evidence. (1) Screening laboratory tests may be considered for all patients with polyneuropathy (Level C). Those tests that provide the highest yield of abnormality are blood glucose, serum B12 with metabolites (methylmalonic acid with or without homocysteine), and serum protein immunofixation electrophoresis (Level C). If there is no definite evidence of diabetes mellitus by routine testing of blood glucose, testing for impaired glucose tolerance may be considered in distal symmetric sensory polyneuropathy (Level C). (2) Genetic testing is established as useful for the accurate diagnosis and classification of hereditary neuropathies (Level A). Genetic testing may be considered in patients with cryptogenic polyneuropathy who exhibit a hereditary neuropathy phenotype (Level C). Initial genetic testing should be guided by the clinical phenotype, inheritance pattern, and electrodiagnostic (EDX) features and should focus on the most common abnormalities, which are CMT1A duplication/HNPP deletion, Cx32 (GJB1), and MFN2 mutation screening. There is insufficient evidence to determine the usefulness of routine genetic testing in patients with cryptogenic polyneuropathy who do not exhibit a hereditary neuropathy phenotype (Level U). Muscle Nerve 39: 116–125, 2009Keywords
This publication has 39 references indexed in Scilit:
- A controlled investigation of the cause of chronic idiopathic axonal polyneuropathyBrain, 2004
- Evaluation of Patients With Symptoms Suggestive of Chronic PolyneuropathyJournal of Clinical Neuromuscular Disease, 2001
- Charcot-Marie-Tooth disease type I and related demyelinating neuropathies: Mutation analysis in a large cohort of Italian familiesHuman Mutation, 2001
- Mutation Testing in Charcot‐Marie‐Tooth NeuropathyAnnals of the New York Academy of Sciences, 1999
- Spectrum of mutations in Finnish patients with Charcot-Marie-Tooth disease and related neuropathiesHuman Mutation, 1998
- Approach to Peripheral Neuropathy and NeuronopathySeminars in Neurology, 1998
- Chronic idiopathic axonal polyneuropathy: a five year follow up.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrationsAmerican Journal of Hematology, 1990
- Neuropsychiatric Disorders Caused by Cobalamin Deficiency in the Absence of Anemia or MacrocytosisNew England Journal of Medicine, 1988
- Chronic cryptogenic polyneuropathyActa Neurologica Scandinavica, 1983